Ocuphire Pharma, Inc.

1.69 USD
+0.01 (+0.60%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ocuphire Pharma, Inc. stock is down -2.31% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 19 June’s closed higher than May.

About Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc. focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, which is in Phase III clinical trial for dim light or night vision disturbances. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases.